HUP0302429A2 - 4-Aminokinazolinok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

4-Aminokinazolinok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0302429A2
HUP0302429A2 HU0302429A HUP0302429A HUP0302429A2 HU P0302429 A2 HUP0302429 A2 HU P0302429A2 HU 0302429 A HU0302429 A HU 0302429A HU P0302429 A HUP0302429 A HU P0302429A HU P0302429 A2 HUP0302429 A2 HU P0302429A2
Authority
HU
Hungary
Prior art keywords
group
het1
optionally substituted
atoms
formula
Prior art date
Application number
HU0302429A
Other languages
English (en)
Inventor
Gerhard Barnickel
Sabine Bernotat-Danielowski
Bertram Cezanne
Ralf Devant
Daljit Dhanoa
Edward Jaeger
Werner Mederski
Mark R. Player
James Rinker
Richard Soll
James Vickers
Bao-Ping Zhao
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of HUP0302429A2 publication Critical patent/HUP0302429A2/hu
Publication of HUP0302429A3 publication Critical patent/HUP0302429A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát IbIX glikoprotein antagonista hatású (I) általánosképletű vegyületek, gyógyászatilag elfogadható sóik és szolvátjaikképezik, ahol a képletben R és R1 jelentése egymástól függetlenül H,A, OH, OA, Hal, N(R5)2, NO2, CN, C(O)R2, CON(R5)2, COOR5,allilcsoport, CH=CH- -COOR5, CH=CHCON(R5)2, SO2A vagy adott esetben Acsoporttal szubsztituált fenilcsoport; R2 és R3 jelentése egymástólfüggetlenül H, A, cikloalkilcsoport, -Het3, -(CH2)o-OR5, -(CH2)o-OR6,-(CH2)o-Het1, -(CH2)o-NR5-Het1, -(CHA)p-(CH2)o-N(R5)2, -(CH2)p-(CHA)p-(CH2)m-Ar, -(CH2)o-Z- -(CH2)q-N(R5)2- vagy (a) vagy (b) általánosképletű csoport, azzal a feltétellel, hogy R2 és R3 nem jelenthetegyöntetűen hidrogénatomot, vagy az NR2R3 rész adott esetbenszubsztituált, 1 vagy 2 N atomot tartalmazó monociklusosheterociklusos csoportot képez; R4 jelentése Ar vagy Het1, ahol Arjelentése adott esetben szubsztituált fenil-, naftil- vagybifenilcsoport, Het1 és Het3 jelentése telített vagy részlegesen vagyteljesen telítetlen, adott esetben szubsztituált 5-10 tagú biciklusosheterociklusos csoport, amely 1 vagy 2 N atomot és/vagy 1 vagy 2 Svagy O atomot tartalmazhat utóbbi S és O atomok csak Het1-revonatkoznak); Y jelentése (CH=CH)m, ahol m értéke 0-6; A jelentése 1-6szénatomos alkilcsoport. Ó
HU0302429A 2000-09-20 2001-09-17 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use HUP0302429A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66611700A 2000-09-20 2000-09-20
PCT/EP2001/010704 WO2002024666A2 (en) 2000-09-20 2001-09-17 4-amino-quinazolines

Publications (2)

Publication Number Publication Date
HUP0302429A2 true HUP0302429A2 (hu) 2003-10-28
HUP0302429A3 HUP0302429A3 (en) 2004-01-28

Family

ID=24672900

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302429A HUP0302429A3 (en) 2000-09-20 2001-09-17 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use

Country Status (14)

Country Link
US (1) US20040044204A1 (hu)
EP (1) EP1318985A2 (hu)
JP (1) JP2004509875A (hu)
KR (1) KR20030061807A (hu)
CN (1) CN1474816A (hu)
AU (1) AU2002213923A1 (hu)
BR (1) BR0114021A (hu)
CA (1) CA2422560A1 (hu)
HU (1) HUP0302429A3 (hu)
MX (1) MXPA03002411A (hu)
NO (1) NO20031267L (hu)
PL (1) PL359918A1 (hu)
WO (1) WO2002024666A2 (hu)
ZA (1) ZA200303069B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220751B2 (en) * 2000-11-02 2007-05-22 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US20050209438A1 (en) * 2004-03-19 2005-09-22 Browne Edward P Starter feed stream acidification in DMC-catalyzed process
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7473884B2 (en) * 2005-04-21 2009-01-06 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. Orientation determination utilizing a cordless device
KR100728763B1 (ko) * 2005-12-13 2007-06-19 주식회사 에스티넷 Ｐｏｎ 또는 ａｏｎ 방식의 방송/통신 융합 ｆｔｔｈ시스템
ES2609335T3 (es) 2009-09-03 2017-04-19 Bristol-Myers Squibb Company Quinazolinas como inhibidores de los canales iónicos de potasio
CN102146076B (zh) * 2010-02-05 2013-12-25 陕西师范大学 苯胺喹唑啉衍生物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55514A (en) * 1866-06-12 Improved machine for tunneling rock
US14679A (en) * 1856-04-15 Joel h
US44442A (en) * 1864-09-27 Dayid nelson
US3970648A (en) * 1974-09-06 1976-07-20 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines
US3974277A (en) * 1974-09-06 1976-08-10 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents
US3973021A (en) * 1974-09-06 1976-08-03 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(phydroxyanilino)quinazoline as a bactericide
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
DK0498722T3 (da) * 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US5598994A (en) * 1995-06-29 1997-02-04 Panduit Corp. Stud engaging device
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PT912559E (pt) * 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
ATE359822T1 (de) * 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
DE60140545D1 (hu) * 2000-03-31 2009-12-31 Nippon Shinyaku Co Ltd

Also Published As

Publication number Publication date
EP1318985A2 (en) 2003-06-18
CA2422560A1 (en) 2002-03-28
BR0114021A (pt) 2003-08-19
JP2004509875A (ja) 2004-04-02
MXPA03002411A (es) 2003-06-19
PL359918A1 (en) 2004-09-06
WO2002024666A2 (en) 2002-03-28
AU2002213923A1 (en) 2002-04-02
KR20030061807A (ko) 2003-07-22
CN1474816A (zh) 2004-02-11
HUP0302429A3 (en) 2004-01-28
NO20031267L (no) 2003-05-19
WO2002024666A3 (en) 2002-09-26
ZA200303069B (en) 2004-07-19
NO20031267D0 (no) 2003-03-19
US20040044204A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
HUP0302221A2 (hu) 4-Amino-kinazolinok, eljárás előállításukra, alkalmazásuk és azokat tartalmazó gyógyszerkészítmények
BE2018C008I2 (hu)
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
TWI255807B (en) Therapeutic agents
BG106906A (en) Purine derivatives
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW369526B (en) Diazabicyclic neurokinin antagonists
HUP0302429A2 (hu) 4-Aminokinazolinok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY135841A (en) Novel benzodioxoles
MXPA05010652A (es) Pirazoles sustituidos.
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
MXPA02011370A (es) Iminoazinas substituidas.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
IL179171A0 (en) Alkyl substituted indoloquinoxalines
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
MXPA03009548A (es) Arilsulfonamidas como agentes antivirales.
NZ331801A (en) Therapeutic agent for diabetes
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
MXPA05010651A (es) Compuestos de pirazol.
SG146681A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
MXPA05010650A (es) Pirazoles sustituidos.